Plain-English translation of NCT06755567 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a special type of MRI analysis can accurately predict how well patients with head and neck squamous cell carcinoma will respond to neoadjuvant therapy — a combination of chemotherapy and PD-1 inhibitor immunotherapy given before surgery. The goal is to use detailed computer analysis of MRI images taken before treatment to identify which patients are most likely to have a complete response to the medication, so doctors can personalize treatment plans.
Currently, doctors cannot reliably predict in advance which patients will benefit most from this treatment combination. Only about 37% of patients achieve complete tumor elimination with this therapy, but doctors have no accurate way to identify these responders beforehand. This research aims to fill that gap by developing an imaging-based prediction tool that could help patients and doctors make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would have MRI scans performed before starting your chemotherapy and immunotherapy combination treatment. After completing two or three courses of this medication, you would undergo surgery as planned. Researchers will analyze your MRI images using advanced computer methods to see if they can accurately predict how your tumor responds to the treatment. Your medical data and imaging results will be collected and studied to help build this predictive tool for future patients.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
China